Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of “Buy” from Brokerages
Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has earned a consensus rating of “Buy” from the nine analysts that are currently covering the firm, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price […]
Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has earned a consensus rating of “Buy” from the nine analysts that are currently covering the firm, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price […]
